about
BRAF inhibitors and radiotherapy for melanoma brain metastases: potential advantages and disadvantages of combination therapyPosterior reversible encephalopathy syndrome in a woman with focal segmental glomerulosclerosis.Ustekinumab as an alternative treatment option for chronic pityriasis rubra pilarisIntracranial abscess due to Mycobacterium avium complex in an immunocompetent host: a case reportCanagliflozin-induced pancreatitis: a rare side effect of a new drug.Rapidly progressive stage IVB mycosis fungoides treated with low-dose total skin electron beam therapyBRAF inhibitor and stereotactic radiosurgery is associated with an increased risk of radiation necrosis.The influence of postoperative lymph node radiation therapy on overall survival of patients with stage III melanoma, a National Cancer Database analysisDomestic Job Shortage or Job Maldistribution? A Geographic Analysis of the Current Radiation Oncology Job Market.Total Skin Electron Beam Therapy in the Treatment of Mycosis Fungoides: A Review of Conventional and Low-Dose Regimens.Visual acuity, oncologic, and toxicity outcomes with 103Pd vs. 125I plaque treatment for choroidal melanoma.Black Pleural Effusion: A Unique Presentation of Metastatic MelanomaSuperior mesenteric artery syndrome: a unique complication following carboplatin-based chemotherapyPrognostic relevance of human papillomavirus infection in anal squamous cell carcinoma: analysis of the national cancer data base.Is less more? Comparing chemotherapy alone with chemotherapy and radiation for high-risk grade 2 glioma: An analysis of the National Cancer Data Base.Angiotensin receptor blockade: a novel approach for symptomatic radiation necrosis after stereotactic radiosurgery.Ipilimumab and Stereotactic Radiosurgery Versus Stereotactic Radiosurgery Alone for Newly Diagnosed Melanoma Brain Metastases.In reply to Royce.Rothia dentocariosa: A Rare Cause of Left-Sided Endocarditis in an Intravenous Drug User.Does size matter? Investigating the optimal planning target volume margin for postoperative stereotactic radiosurgery to resected brain metastases.Racial disparities in breast cancer diagnosis in Central Georgia in the United States.Increase in PD-L1 expression after pre-operative radiotherapy for soft tissue sarcoma.Hemorrhagic and Cystic Brain Metastases Are Associated With an Increased Risk of Leptomeningeal Dissemination After Surgical Resection and Adjuvant Stereotactic RadiosurgeryImpact of intensity modulated radiation therapy on survival in anal cancerProton vs. Photon Radiation Therapy for Primary Gliomas: An Analysis of the National Cancer Data BaseNeoadjuvant Interdigitated Chemoradiotherapy Using Mesna, Doxorubicin, and Ifosfamide for Large, High-grade, Soft Tissue Sarcomas of the Extremity: Improved Efficacy and Reduced ToxicityPost-treatment neutrophil-to-lymphocyte ratio predicts for overall survival in brain metastases treated with stereotactic radiosurgeryHow Histopathologic Tumor Extent and Patterns of Recurrence Data Inform the Development of Radiation Therapy Treatment Volumes in Solid MalignanciesTotal skin electron beam therapy in mycosis fungoides-a shift towards lower dose?Dosimetric Factors Related to Radiation Necrosis After 5-Fraction Radiosurgery for Patients With Resected Brain MetastasesDoes the addition of chemotherapy to neoadjuvant radiotherapy impact survival in high-risk extremity/trunk soft-tissue sarcoma?
P50
Q28076667-7FD988C5-B98B-459D-9FA5-F826DCACDC45Q35542316-ED9D9BB2-0717-43DA-84D5-7899B1006246Q35592460-529ECA47-3726-424B-8135-E1DE9A8A9C4DQ35706161-66A679A0-8E31-49DF-8D37-3A12EC3D3981Q35811434-1C928C82-92ED-4D60-B48A-8CA128D1EE19Q35825986-CC17D6B0-4D4F-44D0-97F6-DF82170E67F6Q37090142-704443F6-5EEE-4E0B-BBD2-630B1EAFBB1CQ37729387-FAC6F18F-B40D-491E-8EE6-91C073150163Q38620685-32C6044E-5085-4A84-8B34-A9AA7C525B8CQ38969439-92DD0535-6805-4D12-99C3-DD5032E73F47Q41625689-36A05F14-C2E6-4EF3-9468-1E24A065DBE8Q41838226-F00566BC-41AA-4EB0-8411-FDB668AE1105Q41887591-7FA49C4D-511A-4A7F-B433-46EFC514A8B9Q47128634-D67912AE-F6CA-4ABC-A716-4A88A940C31BQ47368483-B53D372F-D006-4813-BB5A-D8FCC93CCBD7Q47976057-118456A2-B2D3-499C-8466-95BB3F9FD3A6Q48157478-FACBCEFE-3A39-4F32-9A20-8F071ED5FD4BQ49896328-390780BE-2247-4E3A-94D0-CFA1978E6941Q51822024-52419A21-9CCC-4B4A-BC15-3624EB678B9EQ52574801-15F64605-2CCD-45EB-907B-7CC0C3BFF57DQ53773061-61857145-43F3-4FBA-80F6-2BE571894694Q55084146-39AE3677-349D-4D0A-BB9E-95EBEF196120Q58547512-C0CEF2FB-38F7-446B-B268-1419FF48E1B9Q58806082-F487FB78-7119-4169-9492-7B6FDDA68271Q59805345-A0EB26DB-FE86-4DF4-8397-40E1C41CDE3EQ88755806-4847E56C-6BD7-49A6-B6F8-933A88B11796Q88917850-237AFE72-FA26-454C-9C27-987E5E3A4DDCQ89203689-F52F58B9-72E4-40DF-84B1-AC4EDC61409BQ90332257-445F13DF-8335-4EF4-B7B6-AF9A8B1E18B1Q90505450-2B7D4A42-E719-4CDC-8BDE-02CEBC8EB329Q93144894-4C9F788D-DA25-4458-BA08-3ED925B1932B
P50
description
investigador
@es
researcher
@en
wetenschapper
@nl
name
Mudit Chowdhary
@en
Mudit Chowdhary
@nl
type
label
Mudit Chowdhary
@en
Mudit Chowdhary
@nl
prefLabel
Mudit Chowdhary
@en
Mudit Chowdhary
@nl
P31
P496
0000-0001-8546-6077